XML 80 R69.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
EPS Numerator        
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 3,541 $ 4,473 $ 9,393 $ 7,617
Income from continuing operations attributable to Pfizer Inc. common shareholders 3,541 4,473 9,393 7,617
Discontinued operations––net of tax 0 (8) 25 4
Net income attributable to Pfizer Inc. common shareholders 3,541 4,465 9,419 7,621
Net income attributable to Pfizer Inc. common shareholders $ 3,541 $ 4,465 $ 9,419 $ 7,621
EPS Denominator        
Weighted-average number of common shares outstanding––Basic (in shares) 5,685 5,667 5,682 5,663
Common-share equivalents (in shares) 29 39 29 36
Weighted-average number of common shares outstanding––Diluted (in shares) 5,714 5,705 5,710 5,699
Anti-dilutive common stock equivalents (in shares) [1] 8 25 11 25
[1] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.